Status:
COMPLETED
Sunitinib Malate in Treating Patients With Kidney Cancer
Lead Sponsor:
Centre Antoine Lacassagne
Conditions:
Kidney Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This clinical trial is studying...
Detailed Description
OBJECTIVES: Primary * To determine whether a link exists between the effectiveness of therapy with sunitinib malate and development of blood biomarkers, specifically the angiogenic factors VEGF and ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed renal cell carcinoma
- Metastatic disease requiring first-line treatment with sunitinib malate
- No prior therapy for metastatic disease
- No symptomatic or uncontrolled cerebral metastasis
- PATIENT CHARACTERISTICS:
- Affiliation to the French Social insurance
- Life expectancy ≥ 3 months
- No heart failure
- No chronic unstable disease
- No long QT interval
- No history of another primary cancer
- No severe, uncontrolled acute infection
- No severe, uncontrolled hypertension
- No psychological disorder
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00943839
Start Date
February 1 2009
End Date
December 1 2014
Last Update
November 10 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Antoine Lacassagne
Nice, France, 06189